WINSTON-SALEM, NC–(BUSINESS WIRE)–April 12, 2022–
Javara, a leading Integrated Research Organization (IRO) and pioneer in Clinical Research as an Option of Care (CRAACO), today announced that it has secured a significant strategic growth investment in Series B funding from global growth capital firm General Atlantic. Founded in 2018 by Jennifer Byrne, CEO, Amanda Wright, CDO and Linda McCarty, General Counsel and Chief Privacy Officer, Javara was created with a vision to revolutionize the industry by accelerating access to research – for patients, biopharmaceutical companies and healthcare organizations.
The company intends to leverage this capital to drive geographic expansion and technological advancements, enabling Javara to further propel the integration of clinical research into the healthcare ecosystem and provide access to clinical trials to more patients at the point of care through their trusted physician. Brett Zbar, MD, Managing Director and Global Head of Life Sciences at General Atlantic and Joe von Rickenbach, Senior Advisor at General Atlantic and Co-Founder, Former President and CEO of PAREXEL International Corporation, will join the Board of Directors of Javara.
Javara is reinventing the delivery of clinical research, challenging today’s widely accepted but largely ineffective approach, and bridging the gap between clinical trials and clinical care to enable more patients to participate through access and point-of-care support. Traditional clinical trial sites are autonomous and disconnected from physicians and patient medical records; Javara’s approach is unique, partnering closely with healthcare organizations to integrate research teams and infrastructure along with centralized resources and standardized operations, resulting in greater diversity, retention and quality patient outcomes. Currently, Javara works with an extensive network of leading pharmaceutical, biotechnology and contract research organizations.
“We founded Javara with the goal of transforming the delivery of clinical research, creating a business and technology framework where clinical trials are on the menu of care options for all patients across the healthcare system. Our goal as pioneers of this innovative approach was – and remains – to create a model that drives industry-wide value for all stakeholders, while ensuring that all patients have access to the care they deserve. ‘they deserve,’ said Javara CEO Jennifer Byrne. “We have worked with great urgency and intentionality to overcome long-standing barriers in the industry that impact patient access and engagement in clinical research, and we are thrilled to partner with General Atlantic to bring in more researchers, increase diversity, and respond more effectively to unmet patient needs through the delivery of clinical research as an option for care. General Atlantic brings a wealth of experience in healthcare and life sciences – a landscape rich in opportunity for innovation and technology activation – and their commitment to seeking out and realizing opportunities to advance clinical research. is truly invaluable to our organization and our industry as we look to the future.”
In addition to enabling increased patient access to innovative new care and treatment options, Javara’s approach addresses many of the most critical pain points in clinical trials. On average, traditional stand-alone trial sites enroll only 28% of the targeted number of patients and more than 20% enroll no patients. In addition, nearly 20% of enrolled patients drop out before the end of the trial. As a result, nearly 80% of all trials do not end on time, leading to significant lost revenue for trial sponsors and delays to lifesaving treatments. By introducing patients to clinical trials in familiar, hands-on environments, Javara can more effectively help break down existing socio-economic barriers to reaching diverse patient populations and democratizing a healthcare space in which certain populations lack representation. By providing a positive and personalized patient experience through a trusted support team, the company shortens patient recruitment times and improves patient retention.
“Our partnership with Javara is founded on General Atlantic’s belief that the integrated research model created by Jennifer and her team offers a compelling alternative to traditional on-site clinical investigation, offering the potential to increase efficiency and quality clinical trials and ultimately improve outcomes,” Zbar said. “We look forward to working alongside this seasoned team of innovators and thought leaders to advance Javara’s important mission. .”
“We believe that Javara has developed a creative solution to long-standing obstacles in the clinical trial ecosystem, providing more advantages in predictability, speed, scale, flexibility and diversity over traditional models. he traditional site-based clinical trials at a critical time, as we see trials becoming more complex and expensive. I look forward to supporting the growth of Javara as they continue to shape the future of clinical research,” added von Rickenbach.
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP; Morgan Lewis & Bockius LLP; and HCiT Capital Advisors LLC advised Javara on this Series B funding round.
Javara, the leading integrated research organization (IRO), partners with leading healthcare organizations to provide point-of-care access to clinical trials through integrated research staff and infrastructure. Our access to highly diverse patient populations through their trusted physician ensures that clinical trials are completed with high enrollment and retention rates for delivering quality data. Javara’s centralized resources and standardized operations deliver efficiencies for accelerated study start-up and quality results, so fewer obstacles stand in the way of the product approval process. As pioneers in Clinical Research as an Option for Care (CRAACO), Javara is transforming healthcare and changing lives by connecting the right patients to the right trials at the right time. For more information, please visit Javararesearch.com.
About General Atlantic
General Atlantic is a leading global growth capital firm with more than four decades of experience providing capital and strategic support to more than 445 growth companies throughout its history. Founded in 1980 to partner with visionary entrepreneurs and deliver lasting impact, the firm combines a collaborative global approach, industry expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to develop innovative businesses. around the world. General Atlantic currently has over $84 billion in assets under management across all products as of December 31, 2021, and over 215 investment professionals based in New York, Amsterdam, Beijing, Hong Kong, Jakarta, London, Mexico, Mumbai and Munich. , Palo Alto, São Paulo, Shanghai, Singapore, Stamford and Tel Aviv. For more information on General Atlantic, please visit the website: www.generalatlantic.com.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220412005520/en/
[email protected] Atlantic
Mary Armstrong and Emily Japan
KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA
KEYWORD INDUSTRY: PROFESSIONAL SERVICES HEALTH OTHER PROFESSIONAL SERVICES FINANCE GENERAL HEALTH PHARMACEUTICALS BIOTECHNOLOGY
Copyright BusinessWire 2022.
PUBLISHED: 04/12/2022 07:00 / DISK: 04/12/2022 07:02